Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001128 | 1.00 | MAPT (0.58) | MAPTPOLBCHRNB4CHRNA3RAB9A | |
| SCHEMBL20414145 | 0.83 | CHRNB4 (0.43) | MAPTCHRNB4CHRNA3RAB9ACHRNB2 | |
| SCHEMBL22601593 | 0.83 | MAPT (0.59) | MAPTCHRNB4CHRNA3RAB9AKDM4E | |
| SCHEMBL19012399 | 0.83 | MAPT (0.59) | MAPTCHRNB4CHRNA3RAB9AKDM4E | |
| SCHEMBL20414144 | 0.83 | MAPT (0.40) | MAPTCHRNB4CHRNA3RAB9ACHRNB2 | |
| SCHEMBL20249253 | 0.78 | CHRNB2 (0.61) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22601466 | 0.78 | MAPT (0.42) | MAPTCHRNB4CHRNA3RAB9ACHRNB2 | |
| SCHEMBL20414146 | 0.77 | MAPT (0.43) | MAPTCHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL22601459 | 0.76 | MAPT (0.50) | MAPTGAACHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL22601570 | 0.76 | MAPT (0.43) | MAPTPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | MAPT 4195/4885POLB 4131/4885CHRNB4 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.